Micro-Ultrasound's Ascent: A New Era in Prostate Cancer Diagnostics

NEW YORK, NY – June 30, 2026 – A strategic corporate expansion is often a simple story of market share and revenue. But sometimes, it signals a deeper, more fundamental shift in how we approach critical challenges. The recent announcement by Exact Imaging, a Canadian medtech firm, to significantly expand its U.S. commercial team is one such case. This move isn't just about selling more devices; it's a clear indicator that the landscape of prostate cancer diagnostics is on the cusp of a transformative change, one that promises to bring greater precision and accessibility to patient care.

At the heart of this evolution is the company's high-resolution micro-ultrasound system. While the current gold standard for detecting clinically significant prostate cancer is the costly and often logistically challenging multiparametric MRI (mpMRI), micro-ultrasound is emerging as a powerful and practical contender. Exact Imaging's move to bolster its U.S. sales force, backed by robust clinical data and fresh funding, is a calculated bet that healthcare systems are ready for a new tool that can improve lives by improving the diagnostic process itself.

A New Diagnostic Contender

For years, the pathway for prostate cancer detection has been moving away from random, systematic biopsies—a method with a notoriously high false-negative rate—toward image-guided precision. While mpMRI has led this charge, it comes with significant hurdles. MRI machines are expensive, require specialized facilities and personnel, and can be inaccessible for patients due to long wait times, claustrophobia, or medical contraindications like pacemakers.

This is where micro-ultrasound technology enters the picture, offering a compelling alternative. Exact Imaging’s ExactVu™ platform operates at a frequency of 29 MHz, providing a resolution that is 300% higher than conventional ultrasound and comparable to that of a 3T MRI. This allows urologists, for the first time, to visualize suspicious tissue in real-time and perform a targeted biopsy during the same office visit. It effectively brings the power of high-resolution imaging directly into the urologist's hands, integrating seamlessly into the existing clinical workflow.

This real-time capability is a game-changer. Instead of relying on MRI images taken days or weeks earlier that must be mentally or digitally fused with a live ultrasound, the urologist can see and target lesions directly. This streamlines the process, potentially reducing a multi-appointment journey into a single, more efficient procedure.

Backed by Science: The Clinical Case for Micro-Ultrasound

The growing confidence in micro-ultrasound is not based on convenience alone; it is built on a rapidly expanding foundation of clinical evidence. The most significant validation came in 2025 with the publication of the OPTIMUM randomized clinical trial in the prestigious Journal of the American Medical Association (JAMA). This landmark study, involving 677 men across 19 hospitals in multiple countries, conclusively demonstrated that micro-ultrasound-guided biopsy was noninferior to MRI-fusion-guided biopsy for detecting clinically significant prostate cancer.

This finding has been echoed by subsequent research. A meta-analysis presented at the 2026 ASCO Genitourinary Cancers Symposium further confirmed that micro-ultrasound demonstrated comparable diagnostic accuracy to MRI-targeted biopsies. Critically, some studies have shown that micro-ultrasound can identify significant cancers that were missed by MRI, suggesting it is not just an alternative but a potentially complementary tool that can help close diagnostic gaps. To aid physicians, the technology is supported by the Prostate Risk Identification for Micro-Ultrasound (PRI-MUS) protocol, an evidence-based scoring system that helps standardize image interpretation and identify regions of interest.

This body of evidence, now spanning over 100 peer-reviewed publications, provides the scientific bedrock for the “accelerated demand” that Exact Imaging’s CEO, Randy AuCoin, has cited as the driver for the company’s expansion.

A Strategic Push for Market Leadership

With clinical validation secured, Exact Imaging is now executing a deliberate strategy to translate its technological lead into market dominance. The expansion of its U.S. commercial team is the central pillar of this strategy. The company has promoted Tim Heyer, a U.S. Marine Corps veteran with 35 years of medical device experience, to Vice President of North American Sales. Heyer has a proven track record, having built the sales organization for a pioneering urology product at EDAP Technomed ahead of its FDA approval in the 1990s. His deep experience is complemented by the addition of Drew Moore as Sales Executive for the Northeast, who brings two decades of relationships within the urological community.

“My focus has always been on building strong relationships with physicians and understanding their needs for providing the best care for their patients,” Mr. Heyer stated, reflecting a philosophy that aligns with the technology's patient-centric benefits.

This commercial push is well-funded. In February 2026, the company closed a $10 million financing round explicitly earmarked to accelerate global sales and adoption. This investment, coupled with the transition to a direct sales model in the U.S. in 2025, positions the company to aggressively expand its footprint from major academic centers to community health systems and independent physician practices across the Midwest and West Coast.

Improving Lives by Improving Access

The ultimate value of any medical innovation is measured by its impact on patient lives. The strategic push to place micro-ultrasound technology in more clinics across the country directly addresses the core issue of access. By providing a less expensive, office-based solution for high-resolution imaging, this technology democratizes precision diagnostics.

Patients in smaller communities or at hospitals without on-site MRI capabilities will no longer have to travel or endure long waits for advanced imaging. For the significant number of men who cannot undergo an MRI, it provides a desperately needed high-quality alternative. The ability to perform an imaging scan and a targeted biopsy in a single 15-minute procedure reduces patient anxiety and the logistical burden of multiple appointments.

As U.S. health centers—both academic and community-based—install additional systems, they are voting with their budgets, signaling a growing belief in this new standard of care. With over 300 systems already installed worldwide, Exact Imaging's U.S. expansion is set to significantly increase that number, bringing the benefits of real-time, high-resolution diagnostics to a much broader patient population and reshaping the future of prostate cancer care for the better.